Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Not applicableUnknownNCT04737382
What this trial is testing

Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.

Who this might be right for
Non-small-cell Lung Carcinoma
The Netherlands Cancer Institute 200
Large-scale testing (Phase 3)Enrolling By InvitationNCT04762459
What this trial is testing

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Who this might be right for
Non-small Cell Lung Carcinoma
Chinese Academy of Medical Sciences 606
Testing effectiveness (Phase 2)Looking for participantsNCT06728865
What this trial is testing

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain Metastases+2 more
Li-kun Chen 70
Early research (Phase 1)Study completedNCT02529995
What this trial is testing

Phase I, Study in Chinese NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
AstraZeneca 31
Large-scale testing (Phase 3)Looking for participantsNCT05236946
What this trial is testing

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who this might be right for
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital 190
Testing effectiveness (Phase 2)UnknownNCT05962021
What this trial is testing

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

Who this might be right for
Non Squamous Non Small Cell Lung CancerEGFR Positive Non-small Cell Lung Cancer
Peking University People's Hospital 126
Early research (Phase 1)Active Not RecruitingNCT02503722
What this trial is testing

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 36
Not applicableNot Yet RecruitingNCT05998993
What this trial is testing

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

Who this might be right for
EGF-R Positive Non-Small Cell Lung CancerNon Small Cell Lung CancerEGFR Exon 19 Deletion+2 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 35
Large-scale testing (Phase 3)Study completedNCT02997501
What this trial is testing

T790M Plasma Testing Methodology Comparison and Clinical Validation

Who this might be right for
Lung Cancer
AstraZeneca 256
Large-scale testing (Phase 3)Active Not RecruitingNCT04841811
What this trial is testing

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 192
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421